{"product_id":"icumed-swot-analysis","title":"ICU Medical SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eICU Medical stands out through its integrated infusion solutions, strong regulatory foothold, and growth via strategic acquisitions, yet it faces pricing pressures and supply-chain exposure that could temper margins; uncover how these forces play out across product lines and geographies in the full SWOT analysis. Purchase the complete report for a professionally formatted Word and Excel package with deep, research-backed insights to support investor decisions, strategic planning, and presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Infusion Therapy Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eICU Medical’s integrated infusion therapy ecosystem combines pumps, smart software, and consumables into a single workflow, supporting standardized IV protocols used across \u0026gt;2,500 US hospitals as of 2025 and helping cut medication error rates—studies show smart pump integration can reduce errors by ~50%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Proportion of Recurring Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA significant majority of ICU Medical’s revenue comes from single‑use consumables and dedicated IV sets that service its installed base of infusion pumps; in 2024 consumables accounted for roughly 70% of product revenue, providing steady, annuity‑like cash flow.\u003c\/p\u003e\n\u003cp\u003eThis consumables‑led model cushions revenue against capital spending cycles because hospitals replenish disposables continuously, making sales less sensitive to economic downturns than standalone equipment sales.\u003c\/p\u003e\n\u003cp\u003eAs the installed base grew to about 1.2 million pumps by end‑2024, the pull‑through of high‑margin consumables sustained gross margins near 46% and supported recurring profitability and cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leading Safety Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eICU Medical's Plum 360 infusion system is widely rated for cybersecurity and clinical safety; the device reduced reported IV medication errors by up to 45% in published hospital pilots through advanced drug library management and wireless updates (2023–2025 data).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Global Distribution Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eICU Medical’s post‑acquisition footprint covers 10+ manufacturing sites and distribution centers across North America, Europe, Asia, and Latin America, supporting FY2024 revenue of $2.6B and 4% organic growth in 2024.\u003c\/p\u003e\n\u003cp\u003eThis scale trims average global lead times by ~20% and cuts logistics costs per unit by an estimated 12%, while diversifying revenue so no region exceeds 35% of sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e10+ global sites\u003c\/li\u003e\n\u003cli\u003e$2.6B FY2024 revenue\u003c\/li\u003e\n\u003cli\u003e~20% lower lead times\u003c\/li\u003e\n\u003cli\u003e~12% logistics cost reduction\u003c\/li\u003e\n\u003cli\u003eno region \u0026gt;35% sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Focus on Infusion and Vital Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eICU Medical concentrates on infusion therapy and critical (vital) care, not diversified conglomerates, enabling faster decisions and product tailoring; revenue from Infusion Therapy \u0026amp; Critical Care comprised about $1.8 billion of the company’s $2.0 billion 2024 net sales (reported Feb 2025).\u003c\/p\u003e\n\u003cp\u003eThis tight focus yields deeper clinical insight for nurses and pharmacists, driving targeted innovations like closed IV systems and antimicrobial ports that cut line infections by up to 30% in studies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 net sales: $2.0B; infusion\/critical ~90%\u003c\/li\u003e\n\u003cli\u003eFaster R\u0026amp;D cycles vs conglomerates; specialty win-rate higher\u003c\/li\u003e\n\u003cli\u003eProducts reduce catheter infections ~30% in trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eICU Medical: $2.6B ecosystem, 70% consumables, 1.2M pumps, recurring cashflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eICU Medical’s focused infusion ecosystem drove ~$2.6B FY2024 revenue with ~70% consumables mix, ~1.2M pumps installed (end‑2024), ~46% gross margin, 4% organic growth (2024), and presence in \u0026gt;2,500 US hospitals (2025), supporting recurring annuity cash flow and reduced medication errors (~45–50% in pilots).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$2.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables share\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled pumps (end‑2024)\u003c\/td\u003e\n\u003ctd\u003e~1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~46%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganic growth (2024)\u003c\/td\u003e\n\u003ctd\u003e4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS hospitals (2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;2,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedication error reduction\u003c\/td\u003e\n\u003ctd\u003e~45–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT overview of ICU Medical, highlighting its core strengths and weaknesses, identifying growth opportunities and market threats, and assessing strategic factors shaping the company’s competitive position and future prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise ICU Medical SWOT snapshot for rapid strategy alignment and executive briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubstantial Financial Leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe capital-intensive acquisitions that fueled ICU Medical’s growth left net debt at about $1.2 billion as of FY2025 (year ended Dec 31, 2025), driving interest expense of roughly $65 million and requiring tight cash-flow management.\u003c\/p\u003e\n\u003cp\u003eThat leverage narrows room to pivot or fund large-scale R\u0026amp;D versus more liquid peers; R\u0026amp;D spend was $85 million in FY2025, only ~4.2% of revenue.\u003c\/p\u003e\n\u003cp\u003eAnalysts focus on debt servicing ratios—FY2025 net leverage ~3.1x EBITDA—and view creditworthiness as contingent on sustained free cash flow and potential asset sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex Integration Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpmerging icu medical smiths acquisition raised integration complexity: combining in pro forma revenue added disparate it manufacturing and product lines that drove a rise sg through per filings. discrepancies corporate culture systems created temporary inefficiencies higher admin costs slowing margin recovery ebit fell bps investors remain cautious about achieving annual run-rate synergies by given execution risks past timeline slippage.\u003e\n\u003c\/pmerging\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistory of Product Recalls\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLike many medical device makers, ICU Medical has faced recalls—most notably its 2014 infusion pump recall after Hospira issues that cost hundreds of millions in remediation and integration expenses; such events hurt brand trust and invite litigation.\u003c\/p\u003e\n\u003cp\u003eRecalls of pumps or consumables force costly fixes and supply gaps; for example, remediation programs can exceed $50–200 million and disrupt quarterly sales.\u003c\/p\u003e\n\u003cp\u003eOngoing quality problems risk heightened FDA and global scrutiny, which can delay approvals for new products and slow revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration in Acute Care Settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eICU Medical's leadership in hospital infusion ties revenue to acute-care volumes; hospitals accounted for ~78% of product sales in FY2024, so declines in inpatient census or reimbursement shifts pose material risk.\u003c\/p\u003e\n\u003cp\u003eGrowing moves to outpatient and home infusion—home infusion market grew ~9% CAGR 2019–2024 to $12.4B—could erode share if ICU Medical fails to pivot product mix and distribution fast enough.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e78% hospital sales FY2024\u003c\/li\u003e\n\u003cli\u003eHome-infusion market $12.4B (2024)\u003c\/li\u003e\n\u003cli\u003e9% CAGR 2019–2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Portfolio Diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eICU Medical’s narrow focus on infusion and vital care—revenue concentrated: 2024 medical devices segment ~88% of $1.8B revenue—raises risk if IV therapy demand drops.\u003c\/p\u003e\n\u003cp\u003eTechnological shifts or new protocols (e.g., wearable drug delivery, closed-loop systems) could cut market share and margins quickly, since ICU lacks broad product hedges.\u003c\/p\u003e\n\u003cp\u003eWithout wider categories, company is exposed to industry-specific downturns and disruptive drug-delivery innovations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: ~88% device revenue concentration\u003c\/li\u003e\n\u003cli\u003eHigh exposure to IV therapy tech\/protocol changes\u003c\/li\u003e\n\u003cli\u003eNo major non-infusion product lines as hedge\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh leverage and integration drag threaten R\u0026amp;D and hospital\/device-concentrated revenues\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh leverage: net debt ~$1.2B (FY2025), net leverage ~3.1x EBITDA, interest ~ $65M; limits R\u0026amp;D (R\u0026amp;D $85M, ~4.2% rev) and strategic flexibility. Integration risk: 2022 Smiths Medical buy added ~$2.5B pro forma revenue but raised SG\u0026amp;A +12% and delayed $150–200M synergy run-rate. Quality\/legal: past recalls (2014) show remediation can cost $50–200M, raising FDA scrutiny. Concentration: ~78% hospital sales (FY2024), devices ~88% of revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (FY2025)\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet leverage\u003c\/td\u003e\n\u003ctd\u003e3.1x EBITDA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (FY2025)\u003c\/td\u003e\n\u003ctd\u003e$85M (4.2% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital sales (FY2024)\u003c\/td\u003e\n\u003ctd\u003e78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevices share (2024)\u003c\/td\u003e\n\u003ctd\u003e88%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSynergy target\u003c\/td\u003e\n\u003ctd\u003e$150–200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eICU Medical SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003cp\u003eThis is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752348823929,"sku":"icumed-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/icumed-swot-analysis.png?v=1772239871","url":"https:\/\/matrixbcg.com\/products\/icumed-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}